alexa Rajasekaran Namakkal Soorappan | University of Utah
ISSN: 2329-6607

Cardiovascular Pharmacology: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Rajasekaran Namakkal Soorappan

Rajasekaran Namakkal Soorappan Rajasekaran Namakkal Soorappan
Division of Cardiovascular Medicine
Department of Internal Medicine
University of Utah-School of Medicine
Utah, USA

Dr. Rajasekaran is an Assistant Professor at University of Utah, USA. He did his PhD from University of Madras Biochemistry and post doctorate from University of Utah.

Research Interest

My laboratory is interested in understanding the transcriptional mechanisms for Reductive Stress (RS) in the heart. Nuclear erythroid 2-related factor 2 (Nrf2) is the master transcription factor that regulates numerous (over 100) genes, which code for key antioxidant enzymes. Turning ON or OFF the Nrf2 at will can exert desired effects in the intracellular redox milieu and/or redox signaling to regulate redox sensitive cardio-protective proteins. Investigating the cause-and-effect relationships between the oxidative and reductive conditions in the myocardium will allow us to understand the critical signals that result in physiological and/or pathological consequences leading to the development of cardiac diseases including cardiac hypertrophy, cardiomyopathy, heart failure, myocardial infarction and cardiac arrest. The goal is to define the redox signaling mechanisms in cardiovascular pathophysiology and to develop potential therapeutic measures.
• Nrf2 dependent transcriptional mechanisms for reductive stress in cardiac hypertrophy and cardiomyopathy.
• Developing novel Reductive Stress in vivo (animal) and in vitro (cell) models.
• Identification of potential mutations in Keap1 and Nrf2 genes in the population and studying their impact on reductive stress cardiomyopathy.
• Nrf2 signaling based interventions (physical and drug) to improve clinical conditions associated with oxido-reductive stress in the heart.

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version